Further clinical trials are needed to evaluate the efficacy of combination therapies that inhibit BET and PARP, as this strategy has great potential to improve the prognoses of patients with SCLC with MYC paralog amplification or overexpression. Here, PARP1 is linked to small cell lung carcinoma.